amino acids including D-serine and produces the corresponding α -keto acids, ammonia, and hydrogen peroxide (Dixon and Kleppe, 1965a; Dixon and Kleppe, 1965b) .
In mammals, DAAO is present in kidneys, liver, and brain. Interestingly, two recent independent studies demonstrated that DAAO expression and activity are elevated in schizophrenia (Burnet et al., 2008; Madeira et al., 2008) . Since the highest DAAO activity is found in the kidneys (Curti et al., 1992) , a substantial amount of orally administered D-serine is metabolized there. This contributes to D-serine's rapid clearance and consequently the high dose required for efficacy.
These findings suggest that inhibition of DAAO would exert dual beneficial effects on D-serine therapy, by (i) enhancement of D-serine exposure and (ii) suppression of hydrogen peroxide generation in the kidneys. Thus, DAAO inhibitors might address the issues associated with clinical use of D-serine and salvage the most clinically efficacious glycine modulatory site agonist. 6-Chlorobenzo [d] isoxazol-3-ol (CBIO) is a potent competitive inhibitor of DAAO with a K i value of 100 nM for porcine DAAO (Ferraris et al., 2008) . While its toxicity profile has not been fully established, CBIO has been tested in both mice and rats as treatment for pain with no apparent toxicity (Gong et al., 2011; Lu et al., 2011) . Oral co-administration of CBIO with Dserine enhanced oral bioavailability of D-serine and its levels in prefrontal cortex (Ferraris et al.,
BAC (RP23-450E21, Invitrogen). The deletion removes the glycine that is mutated in the naturally-occurring DAAO-deficient (ddY) mice and the tyrosine that is thought to be catalytically important. Splicing of exon 6 to exon 9 results in a reading frame shift leading to a truncated protein with no homology past exon 6. The mutant allele was introduced into 129SvEv mouse embryonic stem cells (TG-ES01-01 ESM07, Eurogentec) using standard homologous recombination techniques (Joyner, 2000) . Quantitative PCR of Dao gene copy number was used to identify targeted clones (DAOF: 5'-CCCATGATCCTAGCCTTGGTATC-3'; DAOR: 5'-CCCCTTGTATGACCTTAGGTCAGT-3'; DAO probe: 5'-AACTCTCCGTACATCATCCCAGGGTAAAACTCC-3'; PPIAF: 5'
GCCAGGGTGGTGACTTTACAC-3'; PPIAR: 5'-GACAAGATGCCAGGACCTGTATG-3';
PPIA probe: 5'-TGGCGGCAGGTCCATCTACGG-3'). Fluorescent in situ hybridization using the wild-type Dao containing BAC as a probe were used to confirm targeting and the single integration of the targeting vector. Male chimeric mice were generated by injection of the targeted ES cells into C57Bl/6J blastocysts (Nagy et al., 2003) . Chimeric mice were bred with 129SvEv mice to produce F1 heterozygotes. Germline transmission was confirmed by PCR analysis (G3: 5'-CAGGGCAAAGGGACTGAATA-3'; G4: 5'CACTCCACCACCATCGATTA-3'; dNEO2: 5'-ACATAGCGTTGGCTACCCGTGATA-3'). F1 heterozygous males and females were mated to produce F2 wild-type, heterozygous and homozygous null mutant animals. The colony was maintained on a background of 129SvEv under specific pathogen free conditions with unrestricted access to food and water. 
Animal study.
Mice (n = 3-6 for each time point for each group except for wild-type mice treated with D-serine and CBIO wherein n = 2 for T = 120 and 240 min) were orally dosed (10 mL/kg) with either Dserine (30 mg/kg) alone or D-serine (30 mg/kg) in combination with CBIO (30 mg/kg in 10% DMSO: 0.9% saline (w/v)). The mice were then euthanized at 30, 60, 120 and 240 minutes post
dosing. Approximately 1 mL of whole blood was collected from each animal by cardiac puncture into heparinized microcentrifuge tubes, capped, gently inverted a few times and stored on wet ice until centrifugation (10 min at 800 g, 4°C). Thereafter, the top layer of each tube (~ 400 µl plasma) was aspirated via transfer pipette, dispensed into a clean non-heparinized microcentrifuge tube and stored at -80°C until subsequent analyses. Additionally, mouse brains were quickly excised, the cerebellum and the frontal cortex isolated, weighed and stored at -80°C until the time of analyses.
Bioanalysis of D-serine
Methanol was used to extract amino acids (AA) from both plasma and brain samples. Plasma samples were mixed with methanol (20 × volumes, v/v) , vortexed briefly and allowed to stand at room temperature for 2 min. AA extraction procedures from brain tissues were adapted from previously published methods (Morikawa et al., 2001 ). Brain tissues were homogenized and sonicated in 20 × volumes (w/v) of methanol. Proteins in both matrices were removed upon centrifugation at 50,000 g for 15 min at 4°C. Aliquots (plasma -100 μ l, brain -20 μ l) of the supernatant were evaporated to dryness using a vacuum lyophilizer operated at 30°C.
Subsequently, the residues were reconstituted in ultrapure water (50 μ l) and prepped for AA derivatization.
Amino acid derivatization was carried out based on the previously reported methods (Hashimoto et al., 1992) . Sodium-borate buffer was made using 0.4 M boric acid and pH-adjusted to 9.0 with sodium hydroxide. On the day of the analysis, 10 mg each of OPA and Boc-L-Cys were dissolved in 1 ml of methanol and 3.5 ml of borate buffer added to the Boc-L-Cys-OPA mixture (derivatization reagent). A 45-μl volume of derivatization reagent was then added to a vial containing 5 μ l of either the AA standard or the sample. After 2 minutes of derivatization at room temperature, an aliquot (10 μ l) of the derivatized material was introduced into the HPLC system described below.
The HPLC system consisted of a degasser (DGU-14A, Shimadzu, Columbia, MD), pumps ( Phase I and phase II metabolic stability assay for CBIO was conducted in mouse and human liver microsomes. For phase I metabolism, the reaction was carried out with 100 mM potassium phosphate buffer, pH 7.4, in the presence of NADPH regenerating system (1.3 mM NADPH, 3.3 mM glucose 6-phosphate, 3.3 mM MgCl 2 , 0.4 U/mL glucose-6-phosphate dehydrogenase, 50 µM sodium citrate). Reactions in triplicate were initiated by addition of the liver microsomes (mouse or human) to the incubation mixture (compound final concentration was 10 µM; 0.5 mg/mL microsomes). For phase II glucuronidation reaction, CBIO was added to TRIS-HCl buffer (50 mM, pH 7.5) with microsomes (0.5 mg/mL), along with MgCl 2 (8 mM), and alamethicin (25 µg/mL) and pre-incubated at 37ºC. The reaction was initiated (in triplicate) with UDPGA at a final concentration of 2 mM. Controls in the absence NADPH and UDPGA were carried for both phase I and phase II metabolism respectively, to determine the specific cofactor Systemic exposure of D-serine in the three cohorts was evaluated using the AUC last values. The highest plasma exposure to D-serine was achieved in DAAO KO mice with AUC 0-last value of 95768 ± 6234 hr*ng/mL followed by wild type mice co-administered with CBIO (65778 hr*ng/mL) and wild type mice treated with D-serine alone (40648 ± 6602 hr*ng/mL) without 
in vitro Metabolic stability of CBIO
In mouse and human plasma CBIO was found to be stable over a period of 60 min (data not shown). In mouse and human liver microsomal incubations in the presence or absence of NADPH ( Figure 3A and B), no metabolism of CBIO was observed (~100% remaining at the end of a 60 min incubation), suggesting that CBIO is not a substrate of cytochrome P450 enzymes. In microsomes fortified with UDPGA, however, CBIO was rapidly metabolized with 10% (mouse) and 22% (human) of the parent compound remaining after 60 min of incubation ( Figure 3A (Koibuchi et al., 1995) . Similar reabsorption pathway has been proposed for rats (Silbernagl et al., 1999) and it has been reported that the urinary recovery of orally administered D-serine in rats is only 1.2% (Huang et al., 1998) , indicating that D-serine exhibits similar renal pharmacokinetics in mouse and rat kidneys. Thus, it remains unclear why D-serine is nephrotoxic only in rats despite the presence of DAAO in the proximal tubule of both rats (Chan et al., 1979; Le Hir and Dubach, 1981; Usuda et al., 1986 ) and mice (Koibuchi et al., 1995) . The urinary basal levels of D-serine in mice lacking DAAO activity was reported to be significantly higher than those of wild-type mice (Miyoshi et al., 2009) . While these findings appear to suggest a high degree of renal excretion of D-serine, given the low clearance of D-serine in DAAO KO mice, it is more likely a result of shift in steady state concentrations of basal D-serine in serum and kidney due to the loss of DAAO activity.
In contrast to the marked increase in plasma D-serine half-life in DAAO KO mice, there was little difference in C max values between wild-type and DAAO KO mice. This can be attributed to the significantly lower degree of DAAO activity in the liver compared to that of the kidney in rodents (Burch et al., 1958; Nagata et al., 1988) . It is worth noting that humans express DAAO in both the liver and kidney (Holme and Goldberg, 1982) and that inhibition of DAAO in human is expected to increase not only plasma half-life as seen in mice but also C max of oral D-serine by suppressing DAAO-mediated first pass metabolism in the liver.
The pharmaco-enhancing effect of CBIO on D-serine was not nearly as drastic as that of genetic DAAO deletion, particularly at the later time points. This is presumably due to the rapid clearance of CBIO from the circulation. In vivo pharmacokinetic profile of CBIO was recently reported for rodent species (Lange et al., 2011) . As expected from previous studies in which CBIO demonstrated in vivo pharmaco-enhancing effect on D-serine by oral administration (Ferraris et al., 2008) , CBIO was reported to be orally available in mice (F = 29%). While plasma half-life in mice was not reported, terminal elimination half-life in the brain was determined to be 1 hr, likely suggesting similar short half-life of CBIO in plasma. This explains CBIO's inability to maintain high levels of D-serine plasma levels for a sustained period of time.
As expected, CBIO had no effects on plasma levels of co-administered D-serine in DAAO KO mice (data not shown), confirming that CBIO's ability to enhance plasma D-serine levels is predominantly associated with its inhibition of DAAO.
In an attempt to elucidate the mechanism by which CBIO is cleared from the circulation system, in vitro metabolic stability was measured in plasma and liver microsomes from mouse and human. CBIO showed high stability in mouse and human plasma (>95% remaining after 2 hr incubation; data not shown). In liver microsomes from mouse ( Figure 3A ) and human ( Figure   3B ), no significant loss of CBIO was detected in the absence or presence of NADPH. The presence of the chloro group appears to make CBIO resistant to CYP450-mediated oxidation. In liver microsomes containing UPDGA, however, CBIO was metabolized substantially with only 10% (mouse) and 21% (human) of the parent compound remaining at the end of a 60 min incubation ( Figure 3A and B) . The results clearly show that CBIO undergoes phase II glucuronidation in liver. Since CBIO possesses only a single moiety possibly subject to glucuronidation (3-hydroxyl group), the most likely metabolite is CBIO-3-glucuronide (Figure 4 ).
Indeed, we have detected a new peak corresponding to a mass of CBIO-3-glucuronide with an increasing intensity over time in LC/MS (data not shown).
Unfortunately, the 3-hydroxyl group is essential for the high affinity binding of CBIO to the DAAO active site (Ferraris et al., 2008) . Therefore, removal or masking of this functional group is expected to result in a complete loss of inhibitory potency even though it may circumvent glucuronidation. Further structural optimization of the benzo[d]isoxazol-3-ol scaffold requires careful modulation of steric and electronic environment surrounding the hydroxyl group in a way that does not compromise the inhibitory potency while minimizing the degree of glucuronidation.
It is also important to point out that glucuronidation is only one of many possible metabolic reactions that could take place at this site. Other phase II metabolic reactions, particularly methylation and sulfation, are also common at a free OH-group and much attention needs to be paid when structural optimization of CBIO is conducted for the enhancement of metabolic stability. If such improvements do not result in prolonged plasma half-life, the possibility of metabolism by other organs needs to be explored to determine the optimal strategy for further structural optimization.
In the brain, DAAO activity is known to be highest in the cerebellum while relatively low levels of DAAO activity are detected in the cortex. Not surprisingly, D-serine levels in the brain are inversely correlated with the DAAO activity. As shown in Figure 5A , only negligible basal levels of D-serine were detected in the cerebellum of wild-type mice while substantially higher quantities of D-serine were found in the cortex. This is consistent with the previously reported findings in other strains of mice (Morikawa et al., 2001; Labrie et al., 2009) . c AUC extrapolated from AUC last is greater than 25% and hence the AUC 0-∞ value is not reported.
